

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE
ACT OF 1934

For quarterly period ended March 31, 2006

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 0-11576

HARRIS & HARRIS GROUP, INC.

(Exact name of registrant as specified in its charter)

New York 13-3119827

(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)

111 West 57th Street, New York, New York 10019

(Address of Principal Executive Offices) (Zip Code)

(212) 582-0900

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2
of the Exchange Act).

Large Accelerated Filer ☐ Accelerated Filer ☒ Non-Accelerated Filer ☐

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.

Class	Outstanding at May 8, 2006
-----	-----
Common Stock, \$0.01 par value per share	20,756,345 shares

Harris & Harris Group, Inc.
Form 10-Q, March 31, 2006

Page Number

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements.....	1
Consolidated Statements of Assets and Liabilities.....	2
Consolidated Statements of Operations.....	3
Consolidated Statements of Cash Flows.....	4
Consolidated Statements of Changes in Net Assets.....	5
Consolidated Schedule of Investments.....	6
Notes to Consolidated Financial Statements.....	15
Financial Highlights.....	21

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.....	22
Background and Overview.....	22
Results of Operations.....	23
Financial Condition.....	25
Liquidity.....	26
Capital Resources.....	27
Critical Accounting Policies.....	27
Recent Developments - Portfolio Companies.....	28
Forward Looking Statements.....	28
Item 3. Quantitative and Qualitative Disclosures About Market Risk.....	28
Item 4. Controls and Procedures.....	29
PART II. OTHER INFORMATION	
Item 1A. Risk Factors.....	31
Item 6. Exhibits.....	31
Signature.....	32
Exhibit Index.....	33

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

The information furnished in the accompanying consolidated financial statements reflects all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim period presented.

Harris & Harris Group, Inc.(R) (the "Company," "us," "our" and "we"), is an internally managed venture capital company that has elected to be treated as a business development company under the Investment Company Act of 1940 (the "1940 Act"). Certain information and disclosures normally included in the consolidated financial statements in accordance with Generally Accepted Accounting Principles have been condensed or omitted as permitted by Regulation S-X and Regulation S-K. The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2005, contained in our Annual Report on Form 10-K for the year ended December 31, 2005.

On September 25, 1997, our Board of Directors approved a proposal to seek qualification as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code (the "Code"). At that time, we were taxable under Subchapter C of the Code (a "C Corporation"). In order to qualify as a RIC, we must, in general (1) annually, derive at least 90 percent of our gross income from dividends, interest, gains from the sale of securities and similar sources; (2) quarterly, meet certain investment diversification requirements; and (3) annually, distribute at least 90 percent of our investment company taxable income as a dividend. In addition to the requirement that we must annually distribute at least 90 percent of our investment company taxable income, we may either distribute or retain our taxable net capital gains from investments, but any net capital gains not distributed could be subject to corporate level tax. Further, we could be subject to a four percent excise tax to the extent we fail to distribute at least 98 percent of our annual investment company taxable income and would be subject to income tax to the extent we fail to distribute 100 percent of our investment company taxable income.

Because of the specialized nature of our investment portfolio, we generally can satisfy the diversification requirements under Subchapter M of the Code only if we receive a certification from the Securities and Exchange Commission ("SEC") that we are "principally engaged in the furnishing of capital to other corporations which are principally engaged in the development or exploitation of inventions, technological improvements, new processes, or products not previously generally available."

On June 15, 2005, we received SEC certification for 2004, permitting us to qualify for RIC treatment for 2004 (as we had for the years 1999 through 2003). Although the SEC certification for 2004 was issued, there can be no assurance that we will qualify for or receive such certification for subsequent years (to the extent we need additional certification as a result of changes in our portfolio) or that we will actually qualify for Subchapter M treatment in subsequent years. In addition, under certain circumstances, even if we qualified

for Subchapter M treatment in a given year, we might take action in a subsequent year to ensure that we would be taxed in that subsequent year as a C Corporation, rather than as a RIC. On March 29, 2006, we filed for RIC certification under Section 851(e) of the Code for 2005.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

<TABLE>
<CAPTION>

	ASSETS		
		March 31, 2006	December 31,
		(Unaudited)	
		<C>	<C>
2005			
<S>			
Investments, at value (Cost: \$119,208,625 at 3/31/06, \$134,026,747 at 12/31/05).....		\$ 113,731,480	\$
129,438,197			
Cash and cash equivalents.....		4,470,822	
1,213,289			
Restricted funds.....		1,901,078	
1,730,434			
Receivable from portfolio company.....		0	
75,000			
Interest receivable.....		565,259	
248,563			
Prepaid expenses.....		452,030	
2,993			
Other assets.....		218,654	
229,644			
---		-----	-----
Total assets.....		\$ 121,339,323	\$
132,938,120		=====	
=====			
	LIABILITIES & NET ASSETS		
Accounts payable and accrued liabilities.....		\$ 3,410,979	\$
3,174,183			
Accrued profit sharing (Note 4).....		210,786	
2,107,858			
Deferred rent.....		29,302	
31,003			
Current taxes payable.....		1,354,504	
1,514,967			
Taxes payable on behalf of shareholders (Note 6).....		0	
8,122,367			
---		-----	-----
Total liabilities.....		5,005,571	
14,950,378		-----	-----

Net assets.....		\$ 116,333,752	\$
117,987,742		=====	
=====			
Net assets are comprised of:			
Preferred stock, \$0.10 par value, 2,000,000 shares authorized; none issued.....		\$ 0	\$
0			
Common stock, \$0.01 par value, 30,000,000 shares authorized; 22,585,085 issued at 3/31/06 and 12/31/05.....		225,851	
225,851			
Additional paid in capital (Note 7).....		122,149,642	
122,149,642			
Accumulated net realized income.....		3,016,509	
3,781,905			
Accumulated unrealized depreciation of investments.....		(5,652,719)	
(4,764,125)			
Treasury stock, at cost (1,828,740 shares at 3/31/06 and 12/31/05).....		(3,405,531)	
(3,405,531)		-----	-----

Net assets.....	\$	116,333,752	\$
117,987,742			
=====		=====	
Shares outstanding.....		20,756,345	
20,756,345			
=====		=====	
Net asset value per outstanding share.....	\$	5.60	\$
5.68			
=====		=====	

</TABLE>

The accompanying notes are an integral part of these consolidated financial statements.

2

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

<TABLE> <CAPTION>		Three Months Ended	Three Months
Ended		March 31, 2006	March 31,
2005			
Investment income:			
Interest from:			
<S>		<C>	<C>
Fixed income securities	\$	802,362	\$
221,498			
Portfolio companies		0	
38,610			
Miscellaneous income		2,500	
0			
-----		-----	-----
Total investment income		804,862	
260,108			
-----		-----	-----
Expenses:			
Salaries and benefits		786,361	
567,691			
Administration and operations		322,449	
321,961			
Profit-sharing provision (Note 4)		0	
(311,594)			
Professional fees		289,887	
272,465			
Rent		61,238	
48,682			
Directors' fees and expenses		85,902	
85,660			
Depreciation		16,768	
15,269			
Custodian fees		10,000	
5,564			
-----		-----	-----
Total expenses		1,572,605	
1,005,698			
-----		-----	-----
Net operating loss		(767,743)	
(745,590)			
-----		-----	-----
Net realized income (loss) from investments:			
Realized income (loss) from investments		11,953	
(1,036,044)			
Income tax expense (Note 6)		9,606	
4,217			
-----		-----	-----

Net realized income (loss) from investments	2,347	
(1,040,261)		
-		
Net realized loss	(765,396)	
(1,785,851)		
-		
Net increase in unrealized depreciation on investments:		
Change as a result of investment sales	0	
1,363,891		
Change on investments held	(888,594)	
(1,811,487)		
-		
Net increase in unrealized depreciation on investments	(888,594)	
(447,596)		
-		
Net decrease in net assets resulting from operations:		
Total	\$ (1,653,990)	\$
(2,233,447)		
=====	=====	
Per average outstanding share	\$ (0.08)	\$
(0.13)		
=====	=====	
Average outstanding shares	20,756,345	
17,248,845		
=====	=====	

</TABLE>

The accompanying notes are an integral part of these
consolidated financial statements.

3

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

<TABLE>
<CAPTION>

	Three Months Ended March 31, 2006	Three Months Ended March 31, 2005
Cash flows from operating activities:		
<S>	<C>	<C>
Net decrease in net assets resulting from operations	\$ (1,653,990)	\$ (2,233,447)
Adjustments to reconcile net decrease in net assets resulting from operations to net cash (used in) provided by operating activities:		
Net realized and unrealized loss on investments	876,641	1,483,640
Depreciation and amortization	(295,811)	15,269
Changes in assets and liabilities:		
Restricted funds	(170,644)	(7,014)
Receivable from portfolio company	75,000	(7,100)
Interest receivable	(316,696)	(105,467)
Income tax receivable	0	11
Prepaid expenses	(449,037)	121,142
Other assets	0	6,142
Accounts payable and accrued liabilities	236,796	(41,828)
Accrued profit sharing	(1,897,072)	(311,594)
Deferred rent	(1,701)	(1,701)
Current income tax liability	(8,282,830)	0
	-----	-----
Net cash (used in) operating activities	(11,879,344)	(1,081,947)
	-----	-----

Cash flows from investing activities:

Net sale of short-term investments and marketable securities	24,534,942	4,287,322
Investment in private placements and loans	(9,412,764)	(3,782,686)
Proceeds from sale of investments	20,688	355,684
Purchase of fixed assets	(5,989)	(16,749)
	-----	-----
Net cash provided by investing activities	15,136,877	843,571
	-----	-----
Net increase (decrease) in cash and cash equivalents:		
Cash and cash equivalents at beginning of the year .	1,213,289	650,332
Cash and cash equivalents at end of the year	4,470,822	411,956
	-----	-----
Net increase (decrease) in cash and cash equivalents	\$ 3,257,533	\$ (238,376)
	=====	=====
Supplemental disclosures of cash flow information:		
Income taxes paid	\$ 8,291,973	\$ 3,750

</TABLE>

The accompanying notes are an integral part of these
consolidated financial statements.

4

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

<TABLE>
<CAPTION>

	Three Months Ended March 31, 2006 (Unaudited)	Year Ended December 31, 2005
Changes in net assets from operations:		
<S>	<C>	<C>
Net operating loss	\$ (767,743)	\$ (5,465,761)
Net realized income on investments	2,347	14,208,789
Net (increase) in unrealized depreciation on investments as a result of sales	0	(23,181,420)
Net (increase) decrease in unrealized depreciation on investments held	(888,594)	19,790,298
Net change in deferred taxes	0	1,364,470
	-----	-----
Net (decrease) increase in net assets resulting from operations	(1,653,990)	6,716,376
	-----	-----
Changes in net assets from capital stock transactions:		
Proceeds from sale of stock	0	35,075
Additional paid in capital on common stock issued	0	36,491,492
	-----	-----
Net increase in net assets resulting from capital stock transactions	0	36,526,567
	-----	-----
Net (decrease) increase in net assets	(1,653,990)	43,242,943
	-----	-----
Net assets:		
Beginning of the period	117,987,742	74,744,799
	-----	-----
End of the period	\$ 116,333,752	\$ 117,987,742
	=====	=====

</TABLE>

The accompanying notes are an integral part of these
consolidated financial statements.

5

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2006
(Unaudited)

<TABLE>
<CAPTION>

	Method of Valuation (3)	Shares/ Principal	Value
	<C>	<C>	<C>
Investments in Unaffiliated Companies (6)(7) - 13.4% of net assets			
Private Placement Portfolio (Illiquid) - 13.4% of net assets			
AlphaSimplex Group, LLC (2) -- Investment management company headed by Dr. Andrew W. Lo, holder of the Harris & Harris Group Chair at MIT Limited Liability Company Interest.....(B)		--	\$
4,058			-----
-			
Crystal IS, Inc. (1)(2)(5) -- Developing a technology to grow single-crystal boules of aluminum nitride for gallium nitride electronics Series A Convertible Preferred Stock.....(A)		274,100	
199,983			-----
-			
Exponential Business Development Company (1)(2) -- Venture capital partnership focused on early stage companies Limited Partnership Interest.....(B)		--	
0			-----
-			
Molecular Imprints, Inc. (1)(2) -- Manufacturing nanoimprint lithography capital equipment Series B Convertible Preferred Stock.....(A)		1,333,333	
2,000,000			
Series C Convertible Preferred Stock.....(A)		1,250,000	
2,500,000			
Warrants at \$2.00 expiring 12/31/11.....(B)		125,000	
0			-----
-			
4,500,000			
Nanosys, Inc. (1)(2)(5) -- Developing zero and one-dimensional inorganic nanometer-scale materials for use in nanotechnology- enabled systems Series C Convertible Preferred Stock.....(C)		803,428	
2,370,113			
Series D Convertible Preferred Stock.....(C)		1,016,950	
3,000,003			-----
-			
5,370,116			
Nantero, Inc. (1)(2)(5) -- Developing a high-density, nonvolatile, random access memory chip, using nanotechnology Series A Convertible Preferred Stock.....(C)		345,070	
1,046,908			
Series B Convertible Preferred Stock.....(C)		207,051	
628,172			
Series C Convertible Preferred Stock.....(C)		188,315	
571,329			-----
-			
2,246,409			

The accompanying notes are an integral part of these
consolidated financial statements.

<TABLE>
<CAPTION>

Value	Method of Valuation (3)	Shares/ Principal	
-----	-----	-----	-
Investments in Unaffiliated Companies (6)(7) - 13.4% of net assets (cont.)			
Private Placement Portfolio (Illiquid) - 13.4% of net assets (cont.)			
<S>	<C>	<C>	<C>
NeoPhotonics Corporation (1)(2) -- Developing and manufacturing planar optical devices and components			
Common Stock	(C)	716,195	\$
67,736			
Series 1 Convertible Preferred Stock.....	(C)	1,831,256	
2,014,677			
Series 2 Convertible Preferred Stock.....	(C)	741,898	
878,120			
Warrants at \$0.15 expiring 01/26/10.....	(C)	16,364	
164			
Warrants at \$0.15 expiring 12/05/10.....	(C)	14,063	
140			
-----			----
2,960,837			
Polatis, Inc. (1)(2)(5)(10) -- Developing optical networking components by merging materials, MEMS and electronics technologies			
Series A-1 Convertible Preferred Stock.....	(B)	16,775	
47,828			
Series A-2 Convertible Preferred Stock.....	(B)	71,611	
204,172			
-----			----
252,000			
Total Unaffiliated Private Placement Portfolio (cost: \$15,461,334)			
\$15,533,403			----

Total Investments in Unaffiliated Companies (cost: \$15,461,334)			
\$15,533,403			----

</TABLE>

The accompanying notes are an integral part of these
consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2006
(Unaudited)

<TABLE>
<CAPTION>

	Method of Valuation (3)	Shares/ Principal	Value
-----	-----	-----	-----
Investments in Non-Controlled Affiliated Companies (6)(8) - 20.7% of net assets			
Private Placement Portfolio (Illiquid) - 20.7% of net assets			
<S>	<C>	<C>	<C>
BridgeLux, Inc. (1)(2)(11) -- Manufacturing high-power light emitting diodes			
Series B Convertible Preferred Stock.....	(A)	1,861,504	
\$1,000,000			
-			-----
Cambios Technologies Corporation (1)(2)(5) -- Developing commercially relevant materials by evolving biomolecules to express control over nanostructure synthesis			
Series B Convertible Preferred Stock.....	(A)	1,294,025	

1,294,025			
-			
Chlorogen, Inc. (1)(2)(5) -- Developing patented chloroplast technology to produce plant-made proteins			
Series A Convertible Preferred Stock.....(A)	4,478,038		
785,000			
Series B Convertible Preferred Stock.....(A)	2,077,930		
364,261			
-			
1,149,261			
CSwitch, Inc. (1)(2)(5) -- Developing next-generation, system-on-a-chip solutions for communications-based platforms			
Series A Convertible Preferred Stock.....(C)	1,000,000		
500,000			
Series B Convertible Preferred Stock.....(C)	5,700,000		
2,850,000			
-			
3,350,000			
Kereos, Inc. (1)(2)(5) -- Developing molecular imaging agents and targeted therapeutics to image and treat cancer and cardiovascular disease			
Series B Convertible Preferred Stock.....(A)	349,092		
960,000			
-			
Kovio, Inc. (1)(2)(5) -- Developing semiconductor products using printed electronics and thin-film technologies			
Series C Convertible Preferred Stock.....(A)	2,500,000		
3,000,000			
-			
Mersana Therapeutics, Inc. (1)(2)(5)(12) -- Developing advanced polymers for drug delivery			
Series A Convertible Preferred Stock.....(C)	68,452		
136,904			
Series B Convertible Preferred Stock.....(C)	616,500		
1,233,000			
Warrants at \$2.00 expiring 10/21/10.....(B)	91,625		
0			
-			
1,369,904			
Metabolon, Inc. (1)(2)(4)(5) - Discovering biomarkers through the use of metabolomics			
Series B Convertible Preferred Stock.....(A)	2,173,913		
2,500,000			
NanoGram Corporation (1)(2)(5) -- Developing a broad suite of intellectual property utilizing nanotechnology			
Series I Convertible Preferred Stock.....(C)	63,210		
64,259			
Series II Convertible Preferred Stock.....(C)	1,250,904		
1,271,670			
Series III Convertible Preferred Stock.....(C)	1,242,144		
1,262,764			
-			
2,598,693			

</TABLE>

The accompanying notes are an integral part of these
consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2006
(Unaudited)

<TABLE>
<CAPTION>

Method of
Valuation (3)

Shares/
Principal

Value

Investments in Non-Controlled Affiliated Companies (6)(8) - 20.7% of net assets (cont.)			
<S>	<C>	<C>	<C>
Private Placement Portfolio (Illiquid) - 20.7% of net assets (cont.)			
Nanomix, Inc. (1)(2)(5) -- Producing nanoelectronic sensors that integrate carbon nanotube electronics with silicon microstructures			
Series C Convertible Preferred Stock.....(A)	9,779,181	\$	
2,500,000			

NanoOpto Corporation (1)(2)(5) -- Manufacturing discrete and integrated optical communications sub-components on a chip by utilizing nano manufacturing technology			
Series A-1 Convertible Preferred Stock.....(C)	267,857		
32,490			
Series B Convertible Preferred Stock.....(C)	3,819,935		
1,110,073			
Series C Convertible Preferred Stock.....(C)	1,932,789		
842,503			
Warrants at \$0.4359 expiring 03/15/10.....(B)	193,279		
0			

1,985,066			
Nextreme Thermal Solutions, Inc. (1)(2)(5) -- Developing thin-film thermoelectric devices			
Series A Convertible Preferred Stock.....(A)	500,000		
500,000			

Questech Corporation (1)(2) -- Manufacturing and marketing proprietary metal and stone decorative tiles			
Common Stock.....(C)	646,954		
724,588			
Warrants at \$1.50 expiring 08/03/06.....(B)	8,500		
0			
Warrants at \$1.50 expiring 11/21/07.....(B)	3,750		
0			
Warrants at \$1.50 expiring 11/19/08.....(B)	5,000		
0			
Warrants at \$1.50 expiring 11/19/09.....(B)	5,000		
0			

724,588			
Solazyme, Inc. (1)(2)(5) -- Developing energy-harvesting machinery of photosynthetic microbes to produce industrial and pharmaceutical molecules			
Series A Convertible Preferred Stock.....(C)	988,204		
385,400			

Starfire Systems, Inc. (1)(2)(5) --Producing ceramic-forming polymers			
Common Stock.....(A)	375,000		
150,000			
Series A-1 Convertible Preferred Stock.....(C)	600,000		
600,000			

750,000			
Zia Laser, Inc. (1)(2)(5) -- Developing quantum dot semiconductor lasers			
Series C Convertible Preferred Stock.....(B)	1,500,000		
0			

Total Non-Controlled Private Placement Portfolio (cost: \$28,849,560)			
\$24,066,937			

Total Investments in Non-Controlled Affiliated Companies (cost: \$28,849,560)			
\$24,066,937			

</TABLE>			

The accompanying notes are an integral part of these consolidated financial statements.

9

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2006
(Unaudited)

<TABLE>
<CAPTION>

	Method of Valuation (3)	Shares/ Principal	Value
Investments in Controlled Affiliated Companies (6)(9) - 2.4% of net assets			
<S>	<C>	<C>	<C>
Private Placement Portfolio (Illiquid) - 2.4% of net assets			
Evolved Nanomaterial Sciences, Inc. (1)(2)(4)(5) -- Developing nanotechnology-enhanced approaches for the resolution of chiral molecules			
Series A Convertible Preferred Stock.....	(A)	5,870,021	\$
2,800,000			
Total Controlled Private Placement Portfolio (cost: \$2,800,000).....			\$
2,800,000			
---			-----
Total Investments in Controlled Affiliated Companies (cost: \$2,800,000).....			\$
2,800,000			
---			-----
U.S. Government and Government Agency Securities - 61.3% of net assets			
U.S. Treasury Bills -- due date 08/31/06	(J)	15,640,000	
\$15,343,622			
U.S. Treasury Notes -- due date 11/30/07, coupon 4.25%.....	(H)	6,500,000	
6,437,795			
U.S. Treasury Notes -- due date 02/15/08, coupon 3.375%.....	(H)	9,000,000	
8,765,820			
U.S. Treasury Notes -- due date 05/15/08, coupon 3.75%.....	(H)	9,000,000	
8,806,680			
U.S. Treasury Notes -- due date 09/15/08, coupon 3.125%.....	(H)	5,000,000	
4,805,100			
U.S. Treasury Notes -- due date 01/15/09, coupon 3.25%.....	(H)	3,000,000	
2,877,900			
U.S. Treasury Notes -- due date 02/15/09, coupon 4.50%.....	(H)	5,100,000	
5,055,783			
U.S. Treasury Notes -- due date 04/15/09, coupon 3.125%.....	(H)	3,000,000	
2,857,500			
U.S. Treasury Notes -- due date 07/15/09, coupon 3.625%.....	(H)	3,000,000	
2,891,490			
U.S. Treasury Notes -- due date 10/15/09, coupon 3.375%.....	(H)	3,000,000	
2,859,720			
U.S. Treasury Notes -- due date 01/15/10, coupon 3.625%.....	(H)	3,000,000	
2,876,010			
U.S. Treasury Notes -- due date 04/15/10, coupon 4.00%.....	(H)	3,000,000	
2,909,190			
U.S. Treasury Notes -- due date 07/15/10, coupon 3.875%.....	(H)	3,000,000	
2,891,250			
U.S. Treasury Notes -- due date 10/15/10, coupon 4.25%.....	(H)	2,000,000	
1,953,280			
Total Investments in U.S. Government and Government Agency Securities (cost: \$72,097,731).....			
\$71,331,140			
---			-----
Total Investments (cost: \$119,208,625).....			
\$113,731,480			

=====

The accompanying notes are an integral part of these consolidated financial statements.

</TABLE>

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2006
(Unaudited)

Notes to Consolidated Schedule of Investments

- (1) Represents a non-income producing security. Equity investments that have not paid dividends within the last 12 months are considered to be non-income producing.
- (2) Legal restrictions on sale of investment.
- (3) See Footnote to Schedule of Investments for a description of the Valuation Procedures.
- (4) Initial investment was made during 2006.
- (5) These investments are development stage companies. A development stage company is defined as a company that is devoting substantially all of its efforts to establishing a new business, and either it has not yet commenced its planned principal operations, or it has commenced such operations but has not realized significant revenue from them.
- (6) Investments in unaffiliated companies consist of investments in which we own less than five percent of the voting shares of the portfolio company. Investments in non-controlled affiliated companies consist of investments in which we own five percent or more, but less than 25 percent, of the voting shares of the portfolio company or where we hold one or more seats on the portfolio company's Board of Directors. Investments in controlled affiliated companies consist of investments in which we own 25 percent or more of the voting shares of the portfolio company.
- (7) The aggregate cost for federal income tax purposes of investments in unaffiliated companies is \$15,461,334. The gross unrealized appreciation based on the tax cost for these securities is \$1,732,194. The gross unrealized depreciation based on the tax cost for these securities is \$1,660,125.
- (8) The aggregate cost for federal income tax purposes of investments in non-controlled affiliated companies is \$28,849,560. The gross unrealized appreciation based on the tax cost for these securities is \$313,534. The gross unrealized depreciation based on the tax cost for these securities is \$5,096,157.
- (9) The aggregate cost for federal income tax purposes of investments in controlled affiliated companies is \$2,800,000. The gross unrealized appreciation based on the tax cost for these securities is \$0. The gross unrealized depreciation based on the tax cost for these securities is \$0.
- (10) Continuum Photonics, Inc., merged with Polatis, Ltd., to form Polatis, Inc.
- (11) BridgeLux, Inc., was previously named eLite Optoelectronics, Inc.
- (12) Mersana Therapeutics, Inc., was previously named Nanopharma Corp.

The accompanying notes are an integral part of this consolidated schedule.

11

HARRIS & HARRIS GROUP, INC.
FOOTNOTE TO CONSOLIDATED SCHEDULE OF INVESTMENTS
(Unaudited)

VALUATION PROCEDURES

Our investments can be classified into five broad categories for valuation purposes:

- 1) Equity-Related Securities;
- 2) Investments in Intellectual Property or Patents or Research and Development in Technology or Product Development;
- 3) Long-Term Fixed-Income Securities;
- 4) Short-Term Fixed-Income Investments; and
- 5) All Other Investments.

The 1940 Act requires periodic valuation of each investment in our portfolio to determine our net asset value. Under the 1940 Act, unrestricted securities with readily available market quotations are to be valued at the current market value; all other assets must be valued at "fair value" as determined in good faith by or under the direction of the Board of Directors.

Our Board of Directors is responsible for (1) determining overall valuation guidelines and (2) ensuring that our investments are valued within the prescribed guidelines.

Our Valuation Committee, comprised of three or more independent Board members, is responsible for reviewing and approving the valuation of our assets within the guidelines established by the Board of Directors. The Valuation Committee receives information and recommendations from management.

Fair value is generally defined as the amount that an investment could be sold for in an orderly disposition over a reasonable time. Generally, to increase objectivity in valuing our assets, external measures of value, such as public markets or third-party transactions, are utilized whenever possible. Valuation is not based on long-term work-out value, nor immediate liquidation value, nor incremental value for potential changes that may take place in the future.

The values assigned to these investments are based on available information and do not necessarily represent amounts that might ultimately be realized, as such amounts depend on future circumstances and cannot reasonably be determined until the individual investments are actually liquidated or become readily marketable.

Our valuation policy with respect to the five broad investment categories is as follows:

EQUITY-RELATED SECURITIES

Equity-related securities are valued using one or more of the following basic methods of valuation:

A. Cost: The cost method is based on our original cost. This method is generally used in the early stages of a company's development until significant positive or negative events occur subsequent to the date of the original investment that dictate a change to another valuation method. Some examples of these events are: (1) a major recapitalization; (2) a major refinancing; (3) a significant third-party transaction; (4) the development of a meaningful public market for a company's common stock; and (5) significant positive or negative changes in a company's business.

12

B. Analytical Method: The analytical method is generally used to value an investment position when there is no established public or private market in the company's securities or when the factual information available to us dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of our Valuation Committee members, based on the data available to them. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the financial condition and operating results of the company, the long-term potential of the business of the company, the values of similar securities issued by companies in similar businesses, the proportion of the company's securities we own and the nature of any rights to require the company to register restricted securities under applicable securities laws.

C. Private Market: The private market method uses actual, executed, historical transactions in a company's securities by responsible third parties as a basis for valuation. The private market method may also use, where applicable, unconditional firm offers by responsible third parties as a basis for valuation.

D. Public Market: The public market method is used when there is an established public market for the class of a company's securities held by us or into which our securities are convertible. Securities for which market quotations are readily available, and which are not subject to substantial legal or contractual and transfer restrictions, are carried at market value as of the time of valuation. Market value for securities traded on securities exchanges or on the Nasdaq National Market is the last reported sales price on the day of valuation. For other securities traded in the over-the-counter market and listed securities for which no sale was reported on that day, market value is the mean of the closing bid price and asked price on that day. This method is the preferred method of valuation when there is an established public market for a company's securities, as that market provides the most objective basis for valuation. If, for any reason, the Valuation Committee determines that market quotations are not reliable, such securities shall be fair valued by the Valuation Committee in accordance with these valuation procedures. We discount

market value for securities that are subject to significant legal or contractual transfer restrictions.

INVESTMENTS IN INTELLECTUAL PROPERTY, PATENTS, RESEARCH AND DEVELOPMENT IN TECHNOLOGY OR PRODUCT DEVELOPMENT

Such investments are carried at fair value using the following basic methods of valuation:

E. Cost: The cost method is based on our original cost. This method is generally used in the early stages of commercializing or developing intellectual property or patents or research and development in technology or product development until significant positive or adverse events occur subsequent to the date of the original investment that dictate a change to another valuation method.

13

F. Analytical Method: The analytical method is used to value an investment after analysis of the best available outside information where the factual information available to us dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of our Valuation Committee members. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the results of research and development, product development progress, commercial prospects, term of patent, projected markets, and other subjective factors.

G. Private Market: The private market method uses actual third-party investments in the same or substantially similar intellectual property or patents or research and development in technology or product development as a basis for valuation, using actual executed historical transactions by responsible third parties. The private market method may also use, where applicable, unconditional firm offers by responsible third parties as a basis for valuation.

LONG-TERM FIXED INCOME SECURITIES

H. Readily Marketable: Long-term fixed-income securities for which market quotations are readily available are carried at market value as of the time of valuation using the most recent bid quotations when available.

I. Not Readily Marketable: Long-term fixed-income securities for which market quotations are not readily available are carried at fair value as determined in good faith by the Valuation Committee on the basis of available data, which may include credit quality, and interest rate analysis as well as quotations from broker-dealers or, where such quotations are not available, prices from independent pricing services that the Board believes are reasonably reliable and based on reasonable price discovery procedures and data from other sources.

SHORT-TERM FIXED-INCOME INVESTMENTS

J. Short-Term Fixed-Income Investments are valued in the same manner as long-term fixed income securities until the remaining maturity is 60 days or less, after which time such securities may be valued at amortized cost if there is no concern over payment at maturity.

ALL OTHER INVESTMENTS

K. All Other Investments are reported at fair value as determined in good faith by the Valuation Committee.

For all other investments, the reported values shall reflect the Valuation Committee's judgment of fair values as of the valuation date using the outlined basic methods of valuation or any other method of valuation within the prescribed guidelines that the Valuation Committee determines after review and analysis is more appropriate for the particular kind of investment. They do not necessarily represent an amount of money that would be realized if we had to sell such assets in an immediate liquidation. Thus, valuations as of any particular date are not necessarily indicative of amounts that we may ultimately realize as a result of future sales or other dispositions of investments we hold.

14

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1. THE COMPANY

Harris & Harris Group, Inc.(R) (the "Company," "us," "our" and "we"), is a venture capital company operating as a business development company ("BDC") under the Investment Company Act of 1940 ("1940 Act"). We operate as an internally managed company whereby our officers and employees, under the general supervision of our Board of Directors, conduct our operations.

We elected to become a BDC on July 26, 1995, after receiving the necessary governmental approvals. From September 30, 1992, until the election of BDC status, we operated as a closed-end, non-diversified investment company under the 1940 Act. Upon commencement of operations as an investment company, we revalued all of our assets and liabilities in accordance with the 1940 Act. Prior to September 30, 1992, we were registered and filed under the reporting requirements of the Securities and Exchange Act of 1934 as an operating company and, while an operating company, operated directly and through subsidiaries.

Harris & Harris Enterprises, Inc.SM ("Enterprises"), is a 100 percent wholly owned subsidiary of the Company. Enterprises is a partner in Harris Partners I, L.P.SM and is taxed under Subchapter C of the Code (a "C Corporation"). Harris Partners I, L.P., is a limited partnership and owns our interest in AlphaSimplex Group, LLC. The partners of Harris Partners I, L.P., are Enterprises (sole general partner) and Harris & Harris Group, Inc. (sole limited partner).

We filed for the 1999 tax year to elect treatment as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986 (the "Code") and qualified for the same treatment for the years 2000 through 2004. On March 29, 2006, we filed for RIC certification under Section 851(e) of the Code for 2005, however, there can be no assurance that we will qualify as a RIC for 2005 or subsequent years. In addition, under certain circumstances, even if we qualified for Subchapter M treatment for a given year, we might take action in a subsequent year to ensure that we would be taxed in that subsequent year as a C Corporation, rather than as a RIC. As a RIC, we must, among other things, distribute at least 90 percent of our investment company taxable income and may either distribute or retain our realized net capital gains on investments.

NOTE 2. INTERIM FINANCIAL STATEMENTS

Our interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X and in conformity with generally accepted accounting principles applicable to interim financial information. Accordingly, they do not include all information and disclosures necessary for a presentation of our financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America. In the opinion of management, these financial statements reflect all adjustments, consisting only of normal recurring accruals, necessary for a fair presentation of our financial position, results of operations and cash flows for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. These financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2005.

15

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of the consolidated financial statements:

Principles of Consolidation. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for investment companies and include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates. The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities as of March 31, 2006, and December 31, 2005, and the reported amounts of revenues and expenses for the three months ended March 31, 2006 and March 31, 2005. The most significant estimates relate to the fair valuations of certain of our investments. Actual results could differ from these estimates.

Cash and Cash Equivalents. Cash and cash equivalents include money market instruments with maturities of less than three months.

Portfolio Investment Valuations. Investments are stated at "value" as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) the fair value as determined in good faith by, or under the direction of, the Board of Directors for all other assets. (See "Valuation Procedures" in the "Footnote to Consolidated Schedule of

Investments.") At March 31, 2006, our financial statements include private venture capital investments valued at \$42,400,340, the fair values of which were determined in good faith by, or under the direction, of the Board of Directors. Upon sale of investments, the values that are ultimately realized may be different from what is presently estimated. The difference could be material.

Securities Transactions. Securities transactions are accounted for on the date the securities are purchased or sold (trade date); dividend income is recorded on the ex-dividend date; and interest income is accrued as earned. The Company ceases accruing interest when securities are determined to be non-income producing and writes off any previously accrued interest. Realized gains and losses on investment transactions are determined by specific identification for financial reporting and tax reporting.

Income Taxes. Prior to January 1, 1999, we recorded income taxes using the liability method in accordance with the provisions of Statement of Financial Accounting Standards No. 109. Accordingly, deferred tax liabilities had been established to reflect temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases; the most significant such difference related to our unrealized appreciation on investments.

We pay federal, state and local income taxes on behalf of our wholly owned subsidiary, Harris & Harris Enterprises, which is a C corporation. (See "Note 6. Income Taxes.")

16

Restricted Funds. The Company maintains a rabbi trust for the purposes of accumulating funds to satisfy the obligations incurred by us for the Supplemental Executive Retirement Plan ("SERP") under the employment agreement with Charles E. Harris.

Property and Equipment. Property and equipment are included in "Other Assets" and are carried at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the premises and equipment.

NOTE 4. EMPLOYEE PROFIT SHARING PLAN

As of January 1, 2003, we implemented the Amended and Restated Harris & Harris Group, Inc. Employee Profit-Sharing Plan, which we refer to as the 2002 Plan.

The 2002 Plan (and its predecessor) provided for profit sharing by our officers and employees equal to 20 percent of our "qualifying income" for that plan year. For the purposes of the 2002 Plan, qualifying income was defined as net realized income as reflected on our Consolidated Statements of Operations for that year (excluding the profit-sharing expense), less nonqualifying gains, if any.

For purposes of the 2002 Plan, our net realized income included investment income, realized gains and losses, and operating expenses (including taxes paid or payable by us on behalf of shareholders), but was calculated without including dividends paid or distributions made to shareholders, payments under the Plan, accruals for profit sharing, unrealized gains and losses, and loss carry-overs from other years, which net realized income we refer to as qualifying income. The proportion of net after-tax realized gains attributable to asset values as of September 30, 1997, was considered nonqualifying gain, which reduced qualifying income. As soon as practicable following the year-end, the Compensation Committee determined whether, and if so how much, qualifying income existed for a plan year. Ninety percent of the amount determined by the Compensation Committee was then paid out to Plan participants pursuant to the distribution percentages set forth in the 2002 Plan. The remaining 10 percent was paid out after we filed our federal tax return for that plan year.

Under the 2002 Plan, awards previously granted to four individuals who were participants at that time (Charles Harris, Mel Melsheimer, Helene Shavin and Jacqueline Matthews, herein referred to as the "grandfathered participants") were reduced by 10 percent with respect to "Non-Tiny Technology Investments" (as defined in the 2002 Plan) and by 25 percent with respect to "Tiny Technology Investments" (as defined in the 2002 Plan), and these reduced awards became permanent. We refer to these reduced awards as "grandfathered participations." Grandfathered participations covered only investments made prior to the time the 2002 Plan was adopted and did not affect awards related to any investments made after that date. The amount by which the awards of the grandfathered participants were reduced were allocable and reallocable each year by the Compensation Committee among current and new participants as awards under the 2002 Plan.

Notwithstanding any provisions of the 2002 Plan, in no event would the aggregate amount of all awards payable for any Plan Year during which we remained a "business development company" within the meaning of the 1940 Act be greater than 20 percent of our "net income after taxes" within the meaning of Section 57(n)(1)(B) of the 1940 Act. In the event the awards as calculated

exceeded that amount, the 2002 Plan required that the awards be reduced on a pro rata basis.

17

Each quarter, we performed a calculation to determine the accrual for profit-sharing. We calculated 20 percent of qualifying income (i.e. realized income) pursuant to the terms of the 2002 Plan and estimated the amount of additional qualifying income, if any, that would result from selling all the portfolio investments that were valued above cost (i.e., that were in an unrealized appreciation position). Although the accrual would fluctuate as a result of changes in qualifying income and changes in unrealized appreciation, payments were made only to the extent that qualifying income existed. At March 31, 2006 and December 31, 2005, we accrued \$210,786 and \$2,107,858, respectively, for profit sharing as a result of net realized gains. On March 1, 2006, the Company paid \$1,897,072 to plan participants (employees and former employees), which represented 90 percent of the total estimated profit sharing payment for 2005. The balance of \$210,786 is expected to be paid in September 2006. Once the balance of \$210,786 is paid in September, the Company has no further obligations under the 2002 Plan.

On March 23 2006, Board of Directors of the Company voted to terminate the Profit Sharing Plan and established the Harris & Harris Group, Inc. 2006 Equity Incentive Plan (the "Stock Plan"), both subject to shareholder approval. These proposals were approved at the May 4, 2006 Annual Meeting of Shareholders. The Stock Plan provides for the grant of equity-based awards of restricted stock and stock options to our directors, officers, employees, advisors and consultants who are selected by our Compensation Committee for participation in the plan and subject to compliance with the 1940 Act. If the SEC provides exemptive relief to that effect, our Compensation Committee may also authorize awards under the Stock Plan to selected former employees of the Company.

A maximum of 20 percent of our total shares of our common stock issued and outstanding, calculated on a fully diluted basis, will be available for awards under the Stock Plan. Under the Stock Plan, no more than 25 percent of the shares of stock reserved for the grant of the awards under the Stock Plan may be restricted stock awards at any time during the term of the Stock Plan. If any shares of restricted stock are awarded, such awards will reduce on a percentage basis the total number of shares of stock for which options may be awarded. If the Company does not receive exemptive relief from the SEC to issue restricted stock, all shares granted under the Stock Plan may be subject to stock options.

If the Company does receive such exemptive relief and issues 25 percent of the shares of stock reserved for grant under the Stock Plan as restricted stock, no more than 75 percent of the shares granted under the Stock Plan may be subject to stock options. No more than 1,000,000 shares of our common stock may be made subject to awards under the Stock Plan to any individual in any year.

The terms and conditions of stock options granted under the Stock Plan will be determined by the Compensation Committee and set forth in an award agreement between the Company and the award recipient. The exercise price of an option granted under the plan will not be less than the fair market value of our common stock on the date of grant. The vesting of a stock option will be subject to such conditions as the Compensation Committee may determine.

The terms and conditions of awards of restricted stock granted under the Stock Plan will be determined by the Compensation Committee and set forth in an award agreement between the Company and the award recipient. The Compensation Committee may determine that the holder of restricted stock may receive dividends, including deemed dividends, that may be deferred during the restricted period applicable to these awards.

18

Unless earlier terminated by our Board of Directors, the Stock Plan will expire on the 10th anniversary of the date on which it was adopted. The expiration of the Stock Plan will not by itself adversely affect the rights of plan participants under awards that are outstanding at the time the Stock Plan expires. Our Board of Directors may terminate, modify or suspend the plan at any time, provided that no modification of the plan will be effective unless and until any required shareholder approval has been obtained. The Compensation Committee may terminate, modify or amend any outstanding award under the Stock Plan at any time, provided that in such event, the award holder may exercise any vested options prior to such termination of the Stock Plan or award.

We will account for the Stock Plan in accordance with the provisions of SFAS 123(R), "Share-Based Payments," which requires us to record the fair value of the stock-based compensation arrangements on the date they are granted to employees as a liability or as a component of equity, depending on whether the obligations can be settled in cash or stock. Regardless of treatment as liabilities or equity, these amounts must be expensed over the vesting period of the compensation arrangements. Under SFAS 123(R), we will be required to select a valuation technique or option-pricing model that meets the criteria as stated in the standard.

NOTE 5. DISTRIBUTABLE EARNINGS

As of December 31, 2005, and March 31, 2006, there were no distributable earnings. The difference between the book basis and tax basis components of distributable earnings is primarily nondeductible deferred compensation and net operating losses.

NOTE 6. INCOME TAXES

Provided that a proper election is made, a corporation taxable under Subchapter C of the Code or a C Corporation that elects to qualify as a RIC continues to be taxable as a C Corporation on any gains realized within 10 years of its qualification as a RIC (the "Inclusion Period") from sales of assets that were held by the corporation on the effective date of the RIC election ("C Corporation Assets"), to the extent of any gain built into the assets on such date ("Built-In Gain"). If the corporation fails to make a proper election, it is taxable on its Built-In Gain as of the effective date of its RIC election. We had Built-In Gains at the time of our qualification as a RIC and made the election to be taxed on any Built-In Gain realized during the Inclusion Period.

During 2005, we sold our investment in NeuroMetrix, Inc., realized the Built-In Gains, and utilized all of our loss carryforwards.

At March 31, 2006 and December 31, 2005, we had no deferred tax asset or liability.

To the extent that we retain capital gains and declare a deemed dividend to shareholders, the dividend is taxable to the shareholders. We would pay tax on behalf of shareholders, at the corporate rate, on the distribution, and the shareholders would receive a tax credit equal to their proportionate share of the tax paid. We took advantage of this rule for 2005. Included in net realized income from investments for the year ended December 31, 2005, were net realized gains before taxes of \$23,862,037, which consisted primarily of a net realized long term capital gain on the sale of our investment in Neurometrix, Inc., offset by realized net long term capital losses on the sales of Agile Materials & Technologies, Inc., Experion Systems, Inc., Nanotechnologies Inc., and Optiva, Inc. We applied \$140,751 of our capital loss carryforwards and \$501,640 of our pre-1999 loss carryforwards on Built-In Gains to these gains.

19

In December 2005, we declared a deemed dividend on net taxable realized long-term capital gains of \$23,206,763. The Company recorded a tax payable on its Consolidated Statements of Assets and Liabilities of \$8,122,367 for taxes payable on behalf of its shareholders. This distribution of \$8,122,367 was also recorded as an income tax expense on the Consolidated Statements of Operations for the year ended December 31, 2005. Shareholders of record at December 31, 2005, received a tax credit of \$0.39131971 per share. The balance of \$15,084,396 was retained by the Company. The Company paid \$8,122,367 of taxes on behalf of its shareholders on January 30, 2006.

We pay federal, state and local taxes on behalf of our wholly owned subsidiary, Harris & Harris Enterprises, Inc., which is taxed as a C Corporation. For the three months ended March 31, 2006, and 2005, our income tax expense for Harris & Harris Enterprises, Inc, was \$9,606 and \$4,217, respectively.

Continued qualification as a RIC requires us to satisfy certain investment asset diversification requirements in future years. Our ability to satisfy those requirements may not be controllable by us. There can be no assurance that we will qualify as a RIC in subsequent years.

NOTE 7. CAPITAL TRANSACTIONS

In 1998, the Board of Directors approved that effective January 1, 1998, 50 percent of all Directors' fees be used to purchase our common stock from us. However, effective March 1, 1999, the Board of Directors approved that Directors may purchase our common stock in the open market, rather than from us.

Since 1998, we have repurchased a total of 1,859,047 of our shares for a total of \$3,496,388, including commissions and expenses, at an average price of \$1.88 per share. These treasury shares were reduced by the purchases made by the Directors. On July 23, 2002, because of our strategic decision to invest in tiny technology, the Board of Directors reaffirmed its commitment not to authorize the purchase of additional shares of stock in the foreseeable future.

In September of 2005, we completed the sale of an additional 3,507,500 shares for gross proceeds of \$37,091,813; net proceeds of the offering, after offering costs of \$565,246, were \$36,526,567. We intend to use, and have been using, the net proceeds of the offering, less offering costs, to make new investments in tiny technology as well as follow-on investments in our existing venture capital investments, and for working capital.

NOTE 8. SUBSEQUENT EVENTS

On April 10, 2006, we made a \$500,000 follow-on investment in Nextreme Thermal Solutions, Inc.

On April 19, 2006, we made a \$1,750,547 new investment in a privately held, tiny technology company.

On April 20, 2006, we made a \$2,500,000 new investment in privately held Innovalight, Inc.

On May 5, 2006, we made a \$59,403 follow-on investment in a privately held, tiny technology portfolio company.

HARRIS & HARRIS GROUP, INC.
FINANCIAL HIGHLIGHTS
(Unaudited)

<TABLE>
<CAPTION>

	Three Months Ended March 31	
	2006	2005
Per Share Operating Performance		
<S>	<C>	<C>
Net asset value per share, beginning of period	\$ 5.68	\$ 4.33
Net operating income (loss)*	(0.04)	(.04)
Net realized income (loss) on investments*	(0.00)	(.06)
Net increase (decrease) in unrealized appreciation (depreciation) as a result of sales*	(0.00)	.08
Net increase (decrease) in unrealized appreciation (depreciation) on investments held*	(0.04)	(.11)
Total from investment operations*	(0.08)	(.13)
Net decrease as a result of deemed dividend shareholder tax credit	0	0
Total distributions	0	0
Net increase as a result of stock offering	0	0
Total increase from capital stock transactions	0	0
Net asset value per share, end of period	\$ 5.60	\$ 4.20
Stock price per share, end of period	\$ 13.95	\$ 12.04
Total return based on stock price (1)	0.36%	(26.5%)
Supplemental Data:		
Net assets, end of period	\$ 116,333,752	\$ 72,511,352
Ratio of expenses to average net assets (1)	1.3%	1.4%
Ratio of net operating loss to average net assets (1)	(0.7%)	(1.01%)
Cash dividends paid per share	\$ 0	\$ 0
Deemed dividend per share	\$ 0	\$ 0
Number of shares outstanding, end of period	20,756,345	17,248,845

*Based on Average Shares Outstanding.

(1) Not Annualized

</TABLE>

The accompanying notes are an integral part of this schedule.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The information contained in this section should be read in conjunction with the unaudited March 31, 2006, Consolidated Financial Statements and the Company's 2005 audited Consolidated Financial Statements and notes thereto.

Background and Overview

We incorporated under the laws of the state of New York in August 1981. In 1983, we completed an initial public offering and invested \$406,936 in Otisville BioTech, Inc., which also completed an initial public offering later that year. In 1984, Charles E. Harris purchased a controlling interest in us and became the control person in Otisville. We then divested our other assets and became a financial services company, with the investment in Otisville as the initial focus of our business activity. We hired new management for Otisville, and Otisville acquired new technology targeting the development of a human blood substitute.

By 1988, we operated two insurance brokerages and a trust company as wholly-owned subsidiaries. In 1989, Otisville changed its name to Alliance Pharmaceutical Corporation, and by 1990, we had completed selling our \$406,936 investment in Alliance for total proceeds of \$3,923,559.

In 1992, we sold our insurance brokerage and trust company subsidiaries to their respective managements and registered as an investment company under the 1940 Act, commencing operations as a closed-end, non-diversified investment company. In 1995, we elected to become a business development company subject to the provisions of Sections 55 through 65 of the 1940 Act. Throughout our corporate history, we have made early stage venture capital investments in a variety of industries. We define venture capital investments as investments in start-up firms and small businesses with exceptional growth potential. In 1994, we made our first tiny technology investment. From August 2001 through March 31, 2006, all 27 of our initial investments have been exclusively in tiny technology.

Since our investment in Otisville in 1983 through March 31, 2006, we have made a total of 69 venture capital investments, including four private placement investments in securities of publicly traded companies. We have sold 44 of these 69 investments, realizing total proceeds of \$143,614,382 on our invested capital of \$51,144,319. Eighteen of these 44 investments were profitable. As measured from first dollar in to last dollar out, the average and median holding periods for these 44 investments were 3.63 years and 3.18 years, respectively. As measured by the 149 separate rounds of investment within these 44 investments, the average and median holding periods for the 149 separate rounds of investment were 2.85 years and 2.53 years, respectively. At March 31, 2006, we valued the 25 venture capital investments remaining in our portfolio at \$42,400,340, or 36.4 percent of our net assets, including net unrealized depreciation of \$4,710,554. At March 31, 2006, from first dollar in, the average and median holding periods for these 25 venture capital investments were 2.92 years and 1.90 years, respectively. As measured by the 60 separate rounds of investment within these 25 investments, the average and median holding periods for the 60 separate rounds of investment were 2.45 years and 1.78 years, respectively.

We have invested a substantial portion of our assets in venture capital investments of private, development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth, have little or no history of operations and are developing unproven technologies. At March 31, 2006, \$42,400,340, or 36.4 percent, of our net assets at fair value consisted of private venture capital investments, net of unrealized depreciation of \$4,710,554. At December 31, 2005, \$33,187,333, or 28.1 percent, of our net assets at fair value consisted of private venture capital investments, net of unrealized depreciation of \$4,519,009.

We value our private venture capital investments each quarter as determined in good faith by our Valuation Committee, a committee of independent directors, within guidelines established by our Board of Directors in accordance with the 1940 Act. (See "Footnote to Consolidated Schedule of Investments" contained in "Consolidated Financial Statements.")

We have discretion in the investment of our capital. However, we invest primarily in illiquid equity securities of private companies. Generally, these investments take the form of preferred stock, are subject to restrictions on resale and have no established trading market. Our principal objective is to achieve long-term capital appreciation. Therefore, a significant portion of our investment portfolio provides little or no income in the form of dividends or interest. We earn interest income from fixed-income securities, including U.S. government and government agency securities. The amount of interest income we earn varies with the average balance of our fixed-income portfolio and the average yield on this portfolio. Interest income is secondary to capital gains and losses in our results of operations.

We present the financial results of our operations utilizing accounting principles generally accepted in the United States for investment companies. On this basis, the principal measure of our financial performance during any period is the net increase/(decrease) in our net assets resulting from our operating activities, which is the sum of the following three elements:

Net Operating Income / (Loss) - the difference between our income from interest, dividends and fees and our operating expenses.

Net Realized Income / (Loss) on Investments - the difference between the net proceeds of sales of portfolio securities and their stated cost, plus income from interests in limited liability companies.

Net Increase / (Decrease) in Unrealized Appreciation or Depreciation on Investments - the net unrealized change in the value of our investment portfolio.

Owing to the structure and objectives of our business, we generally expect to experience net operating losses and seek to generate increases in our net assets from operations through the long-term appreciation of our venture capital investments. We have relied, and continue to rely, on proceeds from sales of investments, rather than on investment income, to defray a significant portion of our operating expenses. Because such sales are unpredictable, we attempt to maintain adequate working capital to provide for fiscal periods when there are no such sales.

Results of Operations

Three months ended March 31, 2006, as compared to the three months ended March 31, 2005

In the three months ended March 31, 2006, and March 31, 2005, we had net decreases in net assets resulting from operations of \$1,653,990 and \$2,233,447, respectively.

23

Investment Income and Expenses:

We had net operating losses of \$767,743 and \$745,590 for the three months ended March 31, 2006, and March 31, 2005, respectively. The variation in these results is primarily owing to the changes in investment income and operating expenses. During the three months ended March 31, 2006, and 2005, total investment income was \$804,862 and \$260,108, respectively. During the three months ended March 31, 2006, and 2005, total operating expenses were \$1,572,605 and \$1,005,698, respectively.

During the first three months of 2006, as compared with the same period in 2005, investment income increased owing to an increase in our holdings of U.S. Government and Government Agency securities and an increase in interest rates. At March 31, 2006, our holdings of such securities were \$71,331,140 as compared with \$40,191,188 at March 31, 2005.

The increase in operating expenses for the three months ended March 31, 2006, as compared to the three months ended March 31, 2005, was primarily owing to increases in salaries and benefits, profit sharing provision and rental expense. Salaries and benefits increased by \$218,670, or 38.5 percent, through March 31, 2006, as compared to March 31, 2005. The increase in salaries and benefits reflects expenses associated with ten full-time employees and one part-time employee during the first quarter of 2006, as compared with eight full-time employees during the first quarter of 2005. Profit sharing expense was \$0 for the first quarter of 2006, as compared with a reversal of \$(311,594) in 2005. This reversal served to reduce operating expenses by \$311,594 during the first quarter of 2005. Rent expense increased by \$12,556, or 25.8 percent, owing primarily to the additional rent expense for the Palo Alto, California, office.

Realized Income and Losses from Investments:

During the three months ended March 31, 2006, we realized net gains on investments of \$11,953. During the three months ended March 31, 2005, we realized net losses on investments of \$1,036,044.

During the three months ended March 31, 2006, we realized net gains of \$11,953, consisting primarily of proceeds received from the liquidation of Optiva, Inc., offset by losses realized on our investment in AlphaSimplex Group, LLC. During 2005, we deemed the securities we held in Optiva, Inc., worthless and recorded the proceeds received and due to us on the liquidation of our bridge notes, realizing a loss of \$1,619,245. At December 31, 2005, we recorded a \$75,000 receivable for estimated proceeds from the final payment on the Optiva, Inc., bridge notes. During the first quarter of 2006, we received payment of \$95,688 from these bridge notes, resulting in the realized gain of \$20,688 on Optiva, Inc. These gains were offset by losses of \$12,257 on our investment in AlphaSimplex Group, LLC.

During the three months ended March 31, 2005, we realized net losses of \$1,036,044, consisting primarily of a realized loss of \$1,358,286 from the sale of our investment in Agile Materials & Technologies, Inc., offset by a realized gain of \$255,486 resulting from the receipt of funds that were held in escrow for one year from the March 2004 merger of NanoGram Devices Corporation and a wholly owned subsidiary of Wilson Greatbatch Technologies, Inc. In March 2004, we set up a reserve for the escrow of \$255,486, by a charge to realized income from investments. On March 16, 2005, the funds were released from escrow to us, and we released the reserve and recorded the realized income.

24

Net Unrealized Appreciation and Depreciation of Portfolio Securities:

During the three months ended March 31, 2006, net unrealized depreciation on total investments increased by \$888,594, or 19.4 percent, from net unrealized depreciation of \$4,588,550 at December 31, 2005, to net unrealized depreciation of \$5,477,145 at March 31, 2006. Net unrealized depreciation on investments increased by \$447,596, or 37.4 percent, during the three months ended March 31, 2005, from \$1,197,428 at December 31, 2004, to \$1,645,024 at March 31, 2005.

During the three months ended March 31, 2006, net unrealized depreciation on our venture capital investments increased by \$191,545 from \$4,519,009 to \$4,710,554, owing primarily to a decrease in the valuation of our investment in Zia Laser, Inc. Unrealized depreciation on our U.S. Government and Government Agency Securities portfolio increased from \$69,541 at December 31, 2005, to \$766,591 at March 31, 2006.

During the three months ended March 31, 2005, net unrealized depreciation on our venture capital investments increased by \$309,439, from \$874,645 to \$1,184,084, primarily owing to a decrease in the valuation of our investment in NeuroMetrix, Inc., of \$2,250,029, offset by an increase in the valuation of our investment in Nantero, Inc., of \$813,771. In addition, unrealized depreciation decreased by \$1,364,081 as a result of the loss realized on the sale of Agile Materials & Technologies, Inc.

Financial Condition

Three Months ended March 31, 2006

At March 31, 2006, our total assets and net assets were \$121,339,323 and \$116,333,752, respectively, compared with \$132,938,120 and \$117,987,742 at December 31, 2005, respectively.

At March 31, 2006, net asset value per share ("NAV") was \$5.60, as compared with \$5.68 at December 31, 2005. Our shares outstanding remained unchanged during the three months ended March 31, 2006.

Significant developments in the three months ended March 31, 2006, were an increase in the value of our venture capital investments of \$9,213,007 and a decrease in the value of our investment in U.S. government and agency obligations of \$24,919,724. The increase in the value of our venture capital investments, from \$33,187,333 at December 31, 2005, to \$42,400,340 at March 31, 2006, resulted primarily from two new and two follow-on investments, partially offset by a net decrease of \$199,757 in the net value of our previous venture capital investments. The decrease in the value of our U.S. government and agency obligations, from \$96,250,864 at December 31, 2005, to \$71,331,140 at March 31, 2006, is primarily owing to the use of funds for investments totaling \$9,412,764, tax payments of \$8,291,973, profit sharing payments of \$1,897,072, and net operating expenses. In addition, cash increased from \$1,213,289 at December 31, 2005, to \$4,470,822 at March 31, 2006, primarily owing to the maturity of a Treasury Bill on March 31, 2006.

25

The following table is a summary of additions to our portfolio of venture capital investments during the three months ended March 31, 2006:

New Investment	Amount
-----	-----
Evolved Nanomaterial Sciences, Inc.	\$2,800,000
Metabolon, Inc.	\$2,500,000
Follow-on Investment	
CSwitch Corporation	\$2,850,000
NanoGram Corporation	\$1,262,764

Total	\$9,412,764
	=====

The following tables summarize the fair values of our portfolios of venture capital investments and U.S. government and agency obligations, as

compared with their cost, at March 31, 2006, and December 31, 2005:

<TABLE>
<CAPTION>

	March 31, 2006	December 31, 2005
	-----	-----
<S>	<C>	<C>
Venture capital investments, at cost	\$47,110,894	\$37,706,342
Net unrealized depreciation (1)	4,710,554	4,519,009
	-----	-----
Venture capital investments, at fair value	\$42,400,340	\$33,187,333
	=====	=====
	March 31, 2006	December 31, 2005
	-----	-----
U.S. government and agency obligations, at cost	\$72,097,731	\$96,320,405
Net unrealized depreciation(1)	766,591	69,541
	-----	-----
U.S. government and agency obligations, at fair value	\$71,331,140	\$96,250,864
	=====	=====

</TABLE>

1)At March 31, 2006, and December 31, 2005, the net accumulated unrealized depreciation on investments, including deferred taxes, was \$5,652,719 and \$4,764,125, respectively.

The following table summarizes the fair value composition of our venture capital investment portfolio at March 31, 2006, and December 31, 2005.

<TABLE>
<CAPTION>

	March 31, 2006	December 31, 2005
	-----	-----
<S>	<C>	<C>
Category		
Tiny Technology	99.9%	99.9%
Other Venture Capital Investments	0.1%	0.1%
	-----	-----
Total Venture Capital Investments	100.0%	100.0%
	=====	=====

</TABLE>

Liquidity

Our primary sources of liquidity are cash, receivables and freely marketable securities, net of short-term indebtedness. Our secondary sources of liquidity are restricted securities of companies that are publicly traded.

26

At March 31, 2006, and December 31, 2005, our total net primary liquidity was \$76,377,187 and \$97,797,219, respectively, and our secondary liquidity was \$0 and \$0, respectively.

The decrease in our primary liquidity from December 31, 2005, to March 31, 2006, is primarily owing to the use of funds for investments, profit sharing and tax payments, as well as net operating expenses.

Capital Resources

In 2004, we registered with the Securities and Exchange Commission for the sale of up to 7,000,000 shares of our common stock from time to time. In July 2004, we sold 3,450,000 common shares for gross proceeds of \$36,501,000; net proceeds of the offering, after offering costs of \$372,825, were \$36,128,175. In September 2005, we completed the sale of 3,507,500 common shares, for total gross proceeds of \$37,091,813. Net proceeds, after offering costs of \$565,246, were \$36,526,567. We intend to use, and have been using, the net proceeds of the offerings to make new investments in tiny technology as well as follow-on investments in our existing venture capital investments, and for working capital. Through March 31, 2006, we have used \$34,400,685 from these two offerings for these purposes.

Critical Accounting Policies

The Company's significant accounting policies are described in Note 3 to the Consolidated Financial Statements and in the Footnote to the Consolidated Schedule of Investments. Critical accounting policies are those that are both important to the presentation of our financial condition and results of operations and those that require management's most difficult, complex or subjective judgments. The Company considers the following accounting policies

and related estimates to be critical:

Valuation of Portfolio Investments

As a business development company, we invest in illiquid securities including debt and equity securities of private companies. These investments are generally subject to restrictions on resale and generally have no established trading market. We value substantially all of our equity investments at fair value as determined in good faith by our valuation committee on a quarterly basis. The valuation committee, comprised of three or more non-interested board members, reviews and approves the valuation of our investments within the valuation procedures established by the board of directors. Fair value is generally defined as the amount that an investment could be sold for in an orderly disposition over a reasonable time. Generally, to increase objectivity in valuing our assets, external measures of value, such as public markets or third party transactions, are utilized whenever possible. Valuation is not based on long term work-out value, nor immediate liquidation value, nor incremental value for potential changes that may take place in the future. Upon sale of investments, the values that are ultimately realized may be different from what is presently estimated. This difference could be material.

Pension and Post-Retirement Benefit Plan Assumptions

The Company provides a Retirement Healthcare Benefit Plan for employees who meet certain eligibility requirements. Several statistical and other factors that attempt to anticipate future events are used in calculating the expense and liability values related to our post-retirement benefit plans. These factors include assumptions we make about the discount rate, the rate of increase in healthcare costs, and mortality, among others.

27

The discount rate reflects the current rate at which the post retirement benefit liabilities could be effectively settled considering the timing of expected payments for plan participants. In estimating this rate, we consider rates of return on high quality fixed-income investments included in published bond indexes. We consider the Moody's Aa Corporate Bond Index and the Citigroup Pension Liability Index in the determination of the appropriate discount rate assumptions. The weighted average rate we utilized to measure our post retirement benefit obligation as of December 31, 2005, and calculate our 2006 expense was 5.5 percent, which is a decrease from 5.75 percent used in determining the March 2005 expense.

Recent Developments -- Portfolio Companies

On April 10, 2006, we made a \$500,000 follow-on investment in Nextreme Thermal Solutions, Inc.

On April 19, 2006, we made a \$1,750,547 new investment in a privately held, tiny technology company.

On April 20, 2006, we made a \$2,500,000 new investment in privately held InnovaLight, Inc.

On May 5, 2006, we made a \$59,403 follow-on investment in a privately held, tiny technology portfolio company.

Forward-Looking Statements

The information contained herein contains certain forward-looking statements. These statements include the plans and objectives of management for future operations and financial objectives, portfolio growth and availability of funds. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors that could cause actual results and conditions to differ materially from those projected in these forward-looking statements are set forth herein. Other factors that could cause actual results to differ materially include the uncertainties of economic, competitive and market conditions, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that the assumptions underlying the forward-looking statements included herein are reasonable, any of the assumptions could be inaccurate and therefore there can be no assurance that the forward-looking statements included or incorporated by reference herein will prove to be accurate. Therefore, the inclusion of such information should not be regarded as a representation by us or any other person that our plans will be achieved.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our business activities contain elements of risk. We consider the principal types of market risk to be valuation risk and the risk associated with fluctuations in interest rates. Although we are risk-seeking rather than risk-averse in our investments, we consider the management of risk to be essential to our business.

Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) fair value as determined in good faith by, or under the direction of, the Board of Directors for all other assets. (See the "Valuation Procedures" in the "Footnote to Consolidated Schedule of Investments" contained in "Item 1. Consolidated Financial Statements.")

28

Neither our investments nor an investment in us is intended to constitute a balanced investment program.

We have invested a substantial portion of our assets in private development stage or start-up companies. These private businesses tend to be based on new technology and to be thinly capitalized, unproven, small companies that lack management depth and have not attained profitability or have no history of operations. Because of the speculative nature and the lack of a public market for these investments, there is significantly greater risk of loss than is the case with traditional investment securities. We expect that some of our venture capital investments will be a complete loss or will be unprofitable and that some will appear to be likely to become successful but never realize their potential. Even when our private equity investments complete initial public offerings (IPOs), we are normally subject to lock-up agreements for a period of time, and thereafter, the market for the unseasoned publicly traded securities may be relatively illiquid.

Because there is typically no public market for the equity interests of many of the small privately held companies in which we invest, the valuation of the equity interests in that portion of our portfolio is determined in good faith by our Board of Directors in accordance with our Valuation Procedures. In the absence of a readily ascertainable market value, the determined value of our portfolio of equity interests may differ significantly from the values that would be placed on the portfolio if a ready market for the equity interests existed. Any changes in valuation are recorded in our consolidated statements of operations as "Net increase (decrease) in unrealized appreciation on investments."

We also invest in short-term money market instruments, and both short and long-term U.S. government and agency obligations. To the extent that we invest in short and long-term U.S. government and agency obligations, changes in interest rates may result in changes in the value of these obligations which would result in an increase or decrease of our net asset value. The level of interest rate risk exposure at any given point in time depends on the market environment, the expectations of future price and market movements, and the quantity and duration of both the short and long-term U.S. government and agency obligations held by the Company, and it will vary from period to period. If the average interest rate on U. S. government and agency obligations at March 31, 2006, were to increase by 25, 75 and 150 basis points, the weighted average value of these securities held by us at March 31, 2006, would decrease by approximately \$421,130, \$1,263,390 and \$2,526,780, respectively, and our net asset value would decrease correspondingly.

In addition, in the future, we may from time to time opt to borrow money to make investments in the future. Our net investment income will be dependent upon the difference between the rate at which we borrow funds and the rate at which we invest such funds. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income in the event we choose to borrow funds for investing purposes.

Item 4. Controls and Procedures

(a) Disclosure Controls and Procedures. As of the end of the period covered by this report, the Company's management, under the supervision and with the participation of our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as required by Rules 13a-15 of the Securities Exchange Act of 1934 (the "1934 Act")). Disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the issuer's management, as appropriate, to allow timely decisions regarding required disclosures. As of March 31, 2006, based upon this evaluation of our disclosure controls and procedures, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective.

29

(b) Changes in Internal Control Over Financial Reporting. There have been no changes in our internal control over financial reporting that occurred during the first quarter of 2006 to which this report relates that have materially

affected, or are reasonably likely to materially affect, our internal control over financial reporting.

30

PART II. OTHER INFORMATION

Item 1A. Risk Factors

Investing in our shares of common stock involves significant risks relating to our business and investment objective. You should carefully consider the risks and uncertainties described in our Annual Report on Form 10-K for the year ended December 31, 2005, before you purchase any of our shares of common stock. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial also may materially adversely affect our business, financial condition and/or operating results.

Item 6. Exhibits

- | | |
|--------|--|
| 31.01* | Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.02* | Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.01* | Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

*filed herewith

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on behalf of the Registrant and as its chief accounting officer.

Harris & Harris Group, Inc.

/s/ Douglas W. Jamison

By: Douglas W. Jamison, President
and Chief Financial Officer

/s/ Patricia N. Egan

By: Patricia N. Egan
Chief Accounting Officer
and Vice President

Date: May 8, 2006

32

EXHIBIT INDEX

Exhibit No.	Description
-----	-----

- | | |
|-------|--|
| 31.01 | Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.02 | Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.01 | Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

33

Certification of Chief Executive Officer
Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a)

I, Charles E. Harris, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Harris & Harris Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Charles E. Harris

Name: Charles E. Harris
Title: Chief Executive Officer
Date: May 8, 2006

Certification of Chief Financial Officer
Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a)

I, Douglas W. Jamison, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Harris & Harris Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Douglas W. Jamison

Name: Douglas W. Jamison
Title: Chief Financial Officer
Date: May 8, 2006

Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Harris & Harris Group, Inc. (the "Company") for the quarterly period ended March 31, 2006, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles E. Harris, as Chief Executive Officer of the Company, and Douglas W. Jamison, as Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Charles E. Harris

Name: Charles E. Harris
Title: Chief Executive Officer
Date: May 8, 2006

/s/ Douglas W. Jamison

Name: Douglas W. Jamison
Title: Chief Financial Officer
Date: May 8, 2006